Hanmi Pharm Co Ltd 2020 SR
The report highlights Hanmi Pharm's commitment to becoming a global pharmaceutical powerhouse through R&D innovation and sustainable management. In 2019, the company invested KRW 209.8 billion in R&D, representing 18.8% of its revenue, and maintained a pipeline of 31 innovative new drugs. Key achievements include achieving zero industrial and environmental accidents for two consecutive years and becoming the first Korean pharmaceutical company to obtain ISO 22301 certification for business continuity. The company also emphasized ethical management, maintaining an AA grade in the Fair Trade Self-Compliance Program for six consecutive years.
Company: Hanmi Pharm Co Ltd
Sector: Manufacturing
Country: South Korea
Year: 2020
Type: SR
Pages: 51
Hanmi Pharm Co Ltd
The report highlights Hanmi Pharm's commitment to becoming a global pharmaceutical powerhouse through R&D innovation and sustainable management. In 2019, the company invested KRW 209.8 billion in R&D, representing 18.8% of its revenue, and maintained a pipeline of 31 innovative new drugs. Key achievements include achieving zero industrial and environmental accidents for two consecutive years and becoming the first Korean pharmaceutical company to obtain ISO 22301 certification for business continuity. The company also emphasized ethical management, maintaining an AA grade in the Fair Trade Self-Compliance Program for six consecutive years.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Published
May 1, 2020
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women in Management
Workplace Fatalities
Employees